442514-22-9

Basic information

• Product Name: tert-Butyl 3-(methylamino)propylcarbamate
• Synonyms: Boc-3-methylamino-propylcarbamate;tert-Butyl 3-(methylamino)propylcarbamate;1-BOC-AMINO-3-METHYLAMINO-PROPANE-HCl;Boc-3-MethylaMino-propylcarbaMate HCl;Tert-butyl N-[3-(MethylaMino)propyl]carbaMate;(3-Methylamino-propyl)-carbamic acid tert-butyl ester;3-N-Boc-N1-methylpropane-1,3-diamine;N-Boc-3-(methylamino)propanamine
• CAS NO: 442514-22-9
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Mol File: 442514-22-9.mol

Chemical Properties

• Boiling Point: 280.3 °C at 760 mmHg
• Flash Point: 123.3 °C
• Appearance: /
• Density: 0.95 g/cm³
• Vapor Pressure: 0.00381mmHg at 25°C
• Refractive Index: 1.444
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.82±0.46(Predicted)
• CAS DataBase Reference: tert-Butyl 3-(methylamino)propylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(methylamino)propylcarbamate(442514-22-9)
• EPA Substance Registry System: tert-Butyl 3-(methylamino)propylcarbamate(442514-22-9)

Safety Data

• Hazardous Substances Data: 442514-22-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H20N2O2/c1-9(2,3)13-8(12)11-7-5-6-10-4/h10H,5-7H2,1-4H3,(H,11,12)

Upstream product

• 49761-82-2 tert-butyl 1H-imidazole-1-carboxylate 
• 6291-84-5 N-Methyl-1,3-propanediamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 74-89-5 methylamine 
• 1158721-71-1 N-Boc-(3-Cbz-methylaminopropyl)amine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 823190-32-5 tert-butyl-N-(3-{methyl[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)propyl]amino}propyl)carbamate 
• 823190-33-6 tert-butyl-N-(3-{methyl[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)butyl]amino}propyl)carbamate 
• 909804-19-9 (2-{[(3-tert-butoxycarbonylamino-propyl)-methyl-amino]-methyl}-phenyl)-boronic acid 
• 888313-64-2 {3-[(3-chloro-[1,2,4]thiadiazol-5-yl)-methyl-amino]-propyl}-carbamic acid tert-butyl ester 
• 960010-13-3 N-(3-((ethylsulfanylcarbonyl)(methyl)amino)propyl)carbamic acid tert-butyl ester 
• 676351-10-3 tert-butyl-3-{methyl[3-(1-oxido-1,2,4-benzotriazin-3-yl)propyl]amino}propylcarbamate 
• 1052647-52-5 5-(2-amino-6-(2-[3-(tert-butoxycarbonylmethylamino)propylcarbamoyl]ethylsulfanyl)pyrimidin-4-yl)-2,4-dimethyl benzoic acid tert-butyl ester 
• 1253582-18-1 [3-(9H-fluoren-9-ylmethoxycarbonylamino)propyl]methylcarbamic acid tert-butyl ester 
• 289701-05-9 N-[3-(tert. butyloxycarbonylamino)-propyl]-sarcosine ethyl ester 

Relevant articles and documents

Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo

The antioxidant natural product sulforaphane (SFN) is an oil with poor aqueous and thermal stability. Recent work with SFN has sought to optimize methods of formulation for oral and topical administration. Herein we report the design of new analogs of SFN with the goal of improving stability and drug-like properties. Lead compounds were selected based on potency in a cellular screen and physicochemical properties. Among these, 12 had good aqueous solubility, permeability and long-term solid-state stability at 23 °C. Compound 12 also displayed comparable or better efficacy in cellular assays relative to SFN and had in vivo activity in a mouse cigarette smoke challenge model of acute oxidative stress.

LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE

A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS

Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound.

NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES

The present invention discloses a novel method for preparing 3-imidazol-1-yl-[1,2,4]thiadiazole derivatives, particularly to a method of preparing 5-halo-3-imidazol-1-yl-[1,2,4]thiadiazole, more particularly (3 -imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-dialkyl-amines, that afford a high yield of pure product.

COMPLEX COMPOUND AND MRI PROBE MADE OF SAME

Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined.

INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS

The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W' are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention

Nonpeptide inhibitors of cathepsin G: Optimization of a novel β-ketophosphonic acid lead by structure-based drug design

The serine protease cathepsin G (EC 3.4.21.20; Cat G), which is stored in the azurophilic granules of neutrophils (polymorphonuclear leukocytes) and released on degranulation, has been implicated in various pathological conditions associated with inflammation. By employing high-throughput screening, we identified β-ketophosphonic acid 1 as a moderate inhibitor of Cat G (IC50 = 4.1 μM). We were fortunate to obtain a cocrystal of 1 with Cat G and solve its structure by X-ray crystallography (3.5 A). Structural details from the X-ray analysis of 1·Cat G served as a platform for optimization of this lead compound by structure-based drug design. With the aid of molecular modeling, substituents were attached to the 3-position of the 2-naphthyl ring of 1, which occupies the S1 pocket of Cat G, to provide an extension into the hydrophobic S3 region. Thus, we arrived at analogue 7 with an 80-fold potency improvement over 1 (IC50 = 53 nM). From these results, it is evident that the β-ketophosphonic acid unit can form the basis for a novel class of serine protease inhibitors. Copyright